Information Provided By: 
Fly News Breaks for September 24, 2015
KERX
Sep 24, 2015 | 12:21 EDT
Citi analyst Yigal Nochomovitz says the European approval of Fexeric does not change his Sell rating on Keryx Biopharmaceuticals. He keeps a $1.50 price target for the stock. The shares are up 17c to $4.09 in midday trading. The Euopean label contains iron overload/monitoring concerns in like here in the U.S., Nochomovitz tells investors in a research note.
News For KERX From the Last 2 Days
There are no results for your query KERX
